ORIEN and HudsonAlpha announce new research collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE ONCOLOGY RESEARCH INFORMATION EXCHANGE NETWORK (ORIEN) and HudsonAlpha Institute of Biotechnology announced a new collaboration to advance cancer research and care called The ORIEN Avatar Research Program. Under the agreement, HudsonAlpha will provide DNA sequences for 20,000 patient samples, tumor and non-tumor, by 2019 to identify the genetic disturbances and mutations of each patient’s...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login